21:31 , May 28, 2019 |  BC Extra  |  Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

A licensing deal with Lilly for an analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion will receive $47.5 million up front and is eligible for $950 million...
18:30 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Centrexion steps back from IPO amid volatile market

Centrexion Therapeutics Corp. (Boston, Mass.) told BioCentury on Nov. 16 that it will not be moving forward with its NASDAQ IPO. The decision by the pain company comes as market volatility has increased and several...
00:55 , Nov 17, 2018 |  BC Extra  |  Financial News

Centrexion steps back from IPO amid volatile market

A decision by pain company Centrexion Therapeutics Corp. (Boston, Mass.) to not move forward with its NASDAQ IPO comes as market volatility has increased and several biotechs have failed to hit their desired valuations. In...
17:51 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Pain company Centrexion proposes NASDAQ IPO

Pain company Centrexion Therapeutics Corp. (Boston, Mass.) proposed to raise up to $86.3 million in an IPO on NASDAQ. BofA Merrill Lynch, Leerink and Evercore ISI are underwriters. Centrexion expects top-line results from the Phase...
21:10 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Centrexion raises $67M in series D

Centrexion Therapeutics Corp. (Boston, Mass.) raised $67 million on Jan. 2 in a series D round led by New Enterprise Associates, with participation by Quan Capital, ArrowMark Partners, funds advised by Clough Capital Partners, InterWest...
13:15 , Jan 2, 2018 |  BC Extra  |  Financial News

Centrexion raises $67M in series D

Centrexion Therapeutics Corp. (Boston, Mass.) said Tuesday it raised $67 million in a series D round led by New Enterprise Associates, with participation by Quan Capital, ArrowMark Partners, funds advised by Clough Capital Partners, InterWest...
21:30 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Centrexion reports 24-week data from Phase IIb of CNTX-4975 in OA knee pain

Centrexion Therapeutics Corp. (Boston, Mass.) reported additional data from the double-blind, U.S. Phase IIb TRIUMPH trial in 175 patients with chronic, moderate to severe osteoarthritis (OA) knee pain showing that a single intra-articular injection into...
17:03 , Jun 14, 2017 |  BC Extra  |  Clinical News

Centrexion analgesic shows durable effect in Phase IIb

Centrexion Therapeutics Corp. (Boston, Mass.) said a single injection of CNTX-4975 led to a durable effect in the Phase IIb TRIUMPH trial to treat moderate to severe knee pain associated with osteoarthritis (OA). New data...
22:26 , Dec 15, 2016 |  BC Week In Review  |  Clinical News

CNTX-4975: Ph IIb TRIUMPH data

Top-line data from the 24-week, double-blind, U.S. Phase IIb TRIUMPH trial in 175 patients with chronic, moderate to severe OA knee pain showed that a single injection into the knee of 0.5 and 1 mg...
00:03 , Dec 14, 2016 |  BC Extra  |  Clinical News

Centrexion's pain candidate passes Phase IIb test

Centrexion Therapeutics Corp. (Boston, Mass.) said pain candidate CNTX-4975 met the primary endpoint in a Phase IIb study to treat osteoarthritis (OA) knee pain. Compared with placebo, each of two tested doses significantly reduced walking...